Skip to content
Screener

Intangibles (Net) at other companies

Eli Lilly logo
Eli LillyLLY
$18.11B+207%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$7.19M+58.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$24.16M
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$5.79M-17.9%
LQD
Liquidia CorporationLQDA
$2.85M-6.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$26.64M-9.7%

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$712.55M+11.2%
Enterprise value$672.68M+11.0%
P/S-0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0.0×
Current ratio4.3×-1.1×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-340448
Line itemJune 30, 2026December 31, 2025
Prepaid assets and other current assets7,6019,613
Total current assets122,072149,362
Property and equipment, net27,28427,549
Intangible assets, net4,5254,727
Long-term prepayments302112
Deferred tax assets9,2846,873
Long-term certificates of deposit28,44423,516
Other assets, noncurrent7,3447,624

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Gyre Therapeutics, Inc.'s intangibles (net)?
Gyre Therapeutics, Inc. (GYRE) reported intangibles (net) of $4.53M in Q2 2026.
How has Gyre Therapeutics, Inc.'s intangibles (net) changed year-over-year?
Gyre Therapeutics, Inc.'s intangibles (net) decreased by 8.8% year-over-year, from $4.96M to $4.53M.
What is the long-term trend for Gyre Therapeutics, Inc.'s intangibles (net)?
Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s intangibles (net) has grown at a 151.5% compound annual growth rate (CAGR), from $297K to $4.73M.
What does intangibles (net) mean?
Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.

Ask your AI about Gyre Therapeutics, Inc.'s intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude